- Conditions
- Pneumonia, Bacterial
- Interventions
- ME1100 inhalation solution
- Drug
- Lead sponsor
- Meiji Seika Pharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 14
- States / cities
- Martinez, California • Sacramento, California • San Diego, California + 11 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2089–2112
of 10,572
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications
- Interventions
- Observational Protocol
- Other
- Lead sponsor
- European Foundation for Study of Chronic Liver Failure
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3,000 participants
- Timeline
- 2021 – 2026
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Aurora, Colorado • Tampa, Florida + 11 more
- Conditions
- Hypertension
- Interventions
- Firibastat, Placebo
- Drug
- Lead sponsor
- Quantum Genomics SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 515 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Huntington Beach, California • Tustin, California + 11 more
- Conditions
- Ewing Sarcoma, Colorectal Adenocarcinoma
- Interventions
- INBRX-109, Irinotecan, Temozolomide, carboplatin, pemetrexed, Leucovorin, Fluorouracil, Bevacizumab, Trifluridine + Tipiracil
- Drug
- Lead sponsor
- Inhibrx Biosciences, Inc
- Industry
- Eligibility
- 12 Years to 85 Years
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2029
- U.S. locations
- 24
- States / cities
- Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 20 more
- Conditions
- Cardiovascular Disease
- Interventions
- Therapy Programming Report (TPR)
- Behavioral
- Lead sponsor
- Medtronic Cardiac Rhythm and Heart Failure
- Industry
- Eligibility
- Not listed
- Enrollment
- 4,384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 83
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 80 more
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm
- Interventions
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 308
- States / cities
- Little Rock, Arkansas • Fullerton, California • Orange, California + 219 more
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer
- Interventions
- galinpepimut-S, pembrolizumab, Montanide, GM-CSF
- Biological · Other
- Lead sponsor
- Sellas Life Sciences Group
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 12
- States / cities
- Santa Rosa, California • Whittier, California • Miami, Florida + 9 more
- Conditions
- Asthma
- Interventions
- Budesonide/formoterol (SYMBICORT) pMDI, Budesonide HFA pMDI
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 122
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 119 more
- Conditions
- Rheumatic Heart Disease in Children
- Interventions
- CHW Delivered SAP Adherence Supports
- Behavioral
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Depressive Disorder, Major
- Interventions
- Seltorexant, Matching placebo to Seltorexant, Quetiapine XR, Matching placebo to Quetiapine XR
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 757 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 75
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Culver City, California + 62 more
- Conditions
- Osteoporosis
- Interventions
- Teriparatide (PF708), Teriparatide (Forteo)
- Drug
- Lead sponsor
- Pfenex, Inc
- Industry
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 22 more
- Conditions
- Chlamydia Trachomatis, Gonorrhea
- Interventions
- Not listed
- Lead sponsor
- Hologic, Inc.
- Industry
- Eligibility
- 14 Years and older · Female only
- Enrollment
- 1,766 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 15 more
- Conditions
- Angioedema
- Interventions
- Lanadelumab
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 12 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, RO4588161
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • La Jolla, California • Long Beach, California + 26 more
- Conditions
- Influenza
- Interventions
- Baloxavir Marboxil, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 5 Years to 64 Years
- Enrollment
- 4,138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Phoenix, Arizona + 32 more
- Conditions
- Cardiac Disease
- Interventions
- DEFINITY®
- Drug
- Lead sponsor
- Lantheus Medical Imaging
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 15
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 12 more
- Conditions
- Ewing Sarcoma, Ewing Sarcoma of Bone, Ewing Sarcoma of Soft Tissue, Peripheral Primitive Neuroectodermal Tumor, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissue, High-grade Osteosarcoma
- Interventions
- FoundationOne Liquid CDx
- Other
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 12 Months to 50 Years
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Atlanta, Georgia • Boston, Massachusetts + 9 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- BI 10773, Glimepiride, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,549 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more
- Conditions
- Diabetes, Diabetes Mellitus Type 2
- Interventions
- Liraglutide, Metformin, Placebo, NNC0090-2746
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 20
- States / cities
- Chino, California • Hawaiian Gardens, California • Los Angeles, California + 17 more
- Conditions
- Adenoviral Infection
- Interventions
- PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
- Biological
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Burlington, Vermont
- Conditions
- Depression, Healthy
- Interventions
- Quetiapine
- Drug
- Lead sponsor
- University of Cincinnati
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Asthma
- Interventions
- AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 808 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 21
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Fullerton, California + 18 more
- Conditions
- Vaccines, Pneumococcal
- Interventions
- 13-valent Pneumococcal Conjugate Vaccine, 7vPnC
- Biological
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 42 Days to 98 Days
- Enrollment
- 1,712 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 78
- States / cities
- Benton, Arkansas • Conway, Arkansas • Fayetteville, Arkansas + 67 more
- Conditions
- Primary Hyperoxaluria Type 1
- Interventions
- Not listed
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Washington D.C., District of Columbia • Boston, Massachusetts + 5 more